Pasithea Revenue from 2010 to 2024

KTTAW Stock  USD 0.02  0.0003  1.50%   
Pasithea Therapeutics Total Revenue yearly trend continues to be fairly stable with very little volatility. Total Revenue will likely drop to about 362.3 K in 2024.
Check Pasithea Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pasithea Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 680.9 K, Other Operating Expenses of 9.9 M or Total Operating Expenses of 9.8 M, as well as many indicators such as Price To Sales Ratio of 36.39, Dividend Yield of 0.0 or PTB Ratio of 0.38. Pasithea financial statements analysis is a perfect complement when working with Pasithea Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Pasithea Therapeutics Correlation against competitors.

Latest Pasithea Therapeutics' Revenue Growth Pattern

Below is the plot of the Total Revenue of Pasithea Therapeutics Corp over the last few years. Total revenue comprises all receipts Pasithea Therapeutics generated from the sale of its products or services. It is the total amount of income generated by the sale of goods or services related to the company's primary operations. Pasithea Therapeutics' Total Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pasithea Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 486.56 K10 Years Trend
Slightly volatile
   Total Revenue   
       Timeline  

Pasithea Revenue Regression Statistics

Arithmetic Mean105,945
Geometric Mean29,871
Coefficient Of Variation181.12
Mean Deviation145,413
Median15,062
Standard Deviation191,883
Sample Variance36.8B
Range544.5K
R-Value0.67
Mean Square Error21.8B
R-Squared0.45
Significance0.01
Slope28,769
Total Sum of Squares515.5B

Pasithea Revenue History

2024362.3 K
2023559.5 K
2022486.6 K

Other Fundumenentals of Pasithea Therapeutics

Pasithea Therapeutics Revenue component correlations

About Pasithea Therapeutics Financial Statements

Pasithea Therapeutics investors use historical fundamental indicators, such as Pasithea Therapeutics' Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pasithea Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.6 M-2.7 M
Total Revenue559.5 K362.3 K
Cost Of Revenue648.5 K680.9 K
Stock Based Compensation To Revenue 1.97  1.88 
Sales General And Administrative To Revenue 18.36  16.32 
Research And Ddevelopement To Revenue 4.93  4.38 
Capex To Revenue 3.96  2.33 
Revenue Per Share 0.35  0.36 
Ebit Per Revenue(27.41)(28.78)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pasithea Stock Analysis

When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.